Literature DB >> 28733428

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

Alexandre Reuben1,2, Rachel Gittelman3, Jianjun Gao4, Jiexin Zhang5, Erik C Yusko3, Chang-Jiun Wu2, Ryan Emerson3, Jianhua Zhang2, Christopher Tipton3, Jun Li2, Kelly Quek2,6, Vancheswaran Gopalakrishnan1, Runzhe Chen2,6, Luis M Vence7, Tina Cascone6, Marissa Vignali3, Junya Fujimoto8, Jaime Rodriguez-Canales8, Edwin R Parra8, Latasha D Little2, Curtis Gumbs2, Marie-Andrée Forget9, Lorenzo Federico9, Cara Haymaker9, Carmen Behrens8, Sharon Benzeno3, Chantale Bernatchez9, Boris Sepesi10, Don L Gibbons6, Jennifer A Wargo1,2, William N William6, Stephen Swisher10, John V Heymach6, Harlan Robins3,11, J Jack Lee12, Padmanee Sharma4,7, James P Allison7, P Andrew Futreal13, Ignacio I Wistuba14, Jianjun Zhang13,6.   

Abstract

Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of localized lung adenocarcinomas. Recently, mutations, through generation of neoantigens, were shown to alter tumor immunogenicity through T-cell responses. Here, we performed sequencing of the T-cell receptor (TCR) in 45 tumor regions from 11 localized lung adenocarcinomas and observed substantial intratumor differences in T-cell density and clonality with the majority of T-cell clones restricted to individual tumor regions. TCR ITH positively correlated with predicted neoantigen ITH, suggesting that spatial differences in the T-cell repertoire may be driven by distinct neoantigens in different tumor regions. Finally, a higher degree of TCR ITH was associated with an increased risk of postsurgical relapse and shorter disease-free survival, suggesting a potential clinical significance of T-cell repertoire heterogeneity.Significance: The present study provides insights into the ITH of the T-cell repertoire in localized lung adenocarcinomas and its potential biological and clinical impact. The results suggest that T-cell repertoire ITH may be tightly associated to genomic ITH and disease relapse. Cancer Discov; 7(10); 1088-97. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1047. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28733428      PMCID: PMC5628137          DOI: 10.1158/2159-8290.CD-17-0256

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  33 in total

Review 1.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Ultra-sensitive detection of rare T cell clones.

Authors:  Harlan Robins; Cindy Desmarais; Jessica Matthis; Robert Livingston; Jessica Andriesen; Helena Reijonen; Christopher Carlson; Gerold Nepom; Cassian Yee; Karen Cerosaletti
Journal:  J Immunol Methods       Date:  2011-09-10       Impact factor: 2.303

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors:  Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11.

Authors:  Claus Lundegaard; Kasper Lamberth; Mikkel Harndahl; Søren Buus; Ole Lund; Morten Nielsen
Journal:  Nucleic Acids Res       Date:  2008-05-07       Impact factor: 16.971

View more
  62 in total

Review 1.  Intratumoral Immunotherapy for Early-stage Solid Tumors.

Authors:  Wan Xing Hong; Sarah Haebe; Andrew S Lee; C Benedikt Westphalen; Jeffrey A Norton; Wen Jiang; Ronald Levy
Journal:  Clin Cancer Res       Date:  2020-02-18       Impact factor: 12.531

2.  PPP2R2B downregulation is associated with immune evasion and predicts poor clinical outcomes in triple-negative breast cancer.

Authors:  Zheng Li; Yaming Li; Xiaolong Wang; Qifeng Yang
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

3.  Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer.

Authors:  Xiuyun Jiang; Kevin M Sullivan; Yongwoo David Seo; Florencia G Jalikis; Kimberly S Smythe; Arezou Abbasi; Marissa Vignali; James O Park; Sara K Daniel; Seth M Pollack; Teresa S Kim; Raymond Yeung; Ian Nicholas Crispe; Robert H Pierce; Harlan Robins; Venu G Pillarisetty
Journal:  Clin Cancer Res       Date:  2019-04-02       Impact factor: 12.531

4.  Treatment redirection from cure to palliation, then cure again?-a cautious, but urgent matter.

Authors:  Jhingook Kim
Journal:  Transl Lung Cancer Res       Date:  2018-02

5.  Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.

Authors:  Gerald P Linette; Michelle Becker-Hapak; Zachary L Skidmore; Miren Lorea Baroja; Chong Xu; Jasreet Hundal; David H Spencer; Weixuan Fu; Casey Cummins; Maya Robnett; Saghar Kaabinejadian; William H Hildebrand; Vincent Magrini; Ryan Demeter; Alexander S Krupnick; Obi L Griffith; Malachi Griffith; Elaine R Mardis; Beatriz M Carreno
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-04       Impact factor: 11.205

Review 6.  Ushering in Integrated T Cell Repertoire Profiling in Cancer.

Authors:  Ning Jiang; Alexandra A Schonnesen; Ke-Yue Ma
Journal:  Trends Cancer       Date:  2018-12-26

7.  Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

Authors:  Grant M Fischer; Ali Jalali; David A Kircher; Won-Chul Lee; Jennifer L McQuade; Lauren E Haydu; Aron Y Joon; Alexandre Reuben; Mariana P de Macedo; Fernando C L Carapeto; Chendong Yang; Anuj Srivastava; Chandrashekar R Ambati; Arun Sreekumar; Courtney W Hudgens; Barbara Knighton; Wanleng Deng; Sherise D Ferguson; Hussein A Tawbi; Isabella C Glitza; Jeffrey E Gershenwald; Y N Vashisht Gopal; Patrick Hwu; Jason T Huse; Jennifer A Wargo; P Andrew Futreal; Nagireddy Putluri; Alexander J Lazar; Ralph J DeBerardinis; Joseph R Marszalek; Jianjun Zhang; Sheri L Holmen; Michael T Tetzlaff; Michael A Davies
Journal:  Cancer Discov       Date:  2019-02-20       Impact factor: 39.397

8.  Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.

Authors:  Theodore S Hong; Eliezer M Van Allen; Sophia C Kamran; Jochen K Lennerz; Claire A Margolis; David Liu; Brendan Reardon; Stephanie A Wankowicz; Emily E Van Seventer; Adam Tracy; Jennifer Y Wo; Scott L Carter; Henning Willers; Ryan B Corcoran
Journal:  Clin Cancer Res       Date:  2019-06-28       Impact factor: 12.531

Review 9.  Tumour evolution in hepatocellular carcinoma.

Authors:  Amanda J Craig; Johann von Felden; Teresa Garcia-Lezana; Samantha Sarcognato; Augusto Villanueva
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-02       Impact factor: 46.802

10.  Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.

Authors:  Runzhe Chen; Won-Chul Lee; Anne S Tsao; Jianjun Zhang; Junya Fujimoto; Jun Li; Xin Hu; Reza Mehran; David Rice; Stephen G Swisher; Boris Sepesi; Hai T Tran; Chi-Wan Chow; Latasha D Little; Curtis Gumbs; Cara Haymaker; John V Heymach; Ignacio I Wistuba; J Jack Lee; P Andrew Futreal; Jianhua Zhang; Alexandre Reuben
Journal:  Clin Cancer Res       Date:  2020-08-14       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.